Sage Journals: Discover world-class research

Abstract

Purpose:

To observe the curative effect of Xeloda in meibomian gland carcinoma.

Methods:

We treated a 53-year-old woman, who had recrudescent meibomian gland carcinoma, with Xeloda.

Results:

The mass was much smaller with decreased amount of overflow pus after 4 cycles of chemotherapy with Xeloda.

Conclusions:

Xeloda played a significant role in treating recrudescent meibomian gland carcinoma in this patient.

Keywords

Recrudescent carcinoma of meibomian Xeloda

Get full access to this article

View all access options for this article.

References

Gokhan

Sozmen

Ozba

Gungor

Meibomian carcinoma of the eyelid in a Simmental cow.

Vet Ophthalmol. 2010; 13:336–8.

Kumar

Kumar Dorairaj

Prabhakaran

Prakash

Chakraborty

Identification of genes associated with tumorigenesis of meibomian cell carcinoma by microarray analysis.

Genomics. 2007; 90:559–66.

Hayashi

Shima

Kita

Intracranial extension of meibomian gland carcinoma with pagetoid changes.

J Clin Neurosci. 2009; 16:568–70.

Rigas

Kase

Rao

Expression of alpha-crystallins in human sebaceous carcinoma of the eyelid.

Eur J Ophthalmol. 2009; 19:702–7.

Zürcher

Hintschich

Garner

Bunce

Collin

Sebaceous carcinoma of the eyelid: a clinicopathological study.

Br J Ophthalmol. 1998; 82:1049–55.

Hornblass

Lauer

Sebaceous carcinoma of the eyelids.

Ophthalmology. 2004; 111:2149–50.

Leibovitch

Selva

Huilgol

Davis

Dodd

James

Intraepithelial sebaceous carcinoma of the eyelid misdiagnosed as Bowen's disease.

J Cutan Pathol. 2006; 33:303–8.

Husain

Blumenschein

Esmaeli

Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.

Int J Dermatol. 2008; 47:276–9.

Pandey

Singh